BRPI0906634A2 - Drivados de indol 2-carboxamidas e de azaindol 2-carboxamidas substituídos por grupo sinanila, sua preparação e sua aplicação em terapêutica - Google Patents
Drivados de indol 2-carboxamidas e de azaindol 2-carboxamidas substituídos por grupo sinanila, sua preparação e sua aplicação em terapêuticaInfo
- Publication number
- BRPI0906634A2 BRPI0906634A2 BRPI0906634-9A BRPI0906634A BRPI0906634A2 BR PI0906634 A2 BRPI0906634 A2 BR PI0906634A2 BR PI0906634 A BRPI0906634 A BR PI0906634A BR PI0906634 A2 BRPI0906634 A2 BR PI0906634A2
- Authority
- BR
- Brazil
- Prior art keywords
- carboxamides
- sinanyl
- azaindol
- preparation
- therapeutic application
- Prior art date
Links
- VFHUJFBEFDVZPJ-UHFFFAOYSA-N 1h-indole-2-carboxamide Chemical class C1=CC=C2NC(C(=O)N)=CC2=C1 VFHUJFBEFDVZPJ-UHFFFAOYSA-N 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
- C07F7/0814—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring is substituted at a C ring atom by Si
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0800343A FR2926553B1 (fr) | 2008-01-23 | 2008-01-23 | Derives d'indole-2-carboxamides et d'azaindole-2- carboxamides substitues par un groupe silanyle, leur preparation et leur application en therapeutique |
| PCT/FR2009/000054 WO2009109710A1 (fr) | 2008-01-23 | 2009-01-20 | Derives d'indole 2-carboxamides et d'azaindole 2-carboxamides substitues par un groupe silanyle, leur preparation et leur application en therapeutique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0906634A2 true BRPI0906634A2 (pt) | 2015-07-14 |
Family
ID=39671700
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0906634-9A BRPI0906634A2 (pt) | 2008-01-23 | 2009-01-20 | Drivados de indol 2-carboxamidas e de azaindol 2-carboxamidas substituídos por grupo sinanila, sua preparação e sua aplicação em terapêutica |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US8399491B2 (pt) |
| EP (1) | EP2235003B1 (pt) |
| JP (1) | JP5508287B2 (pt) |
| KR (1) | KR20100115358A (pt) |
| CN (1) | CN102143956B (pt) |
| AR (1) | AR070214A1 (pt) |
| AU (1) | AU2009221032B2 (pt) |
| BR (1) | BRPI0906634A2 (pt) |
| CA (1) | CA2712921C (pt) |
| CL (1) | CL2009000127A1 (pt) |
| CO (1) | CO6220974A2 (pt) |
| EA (1) | EA201070874A1 (pt) |
| FR (1) | FR2926553B1 (pt) |
| IL (1) | IL207079A0 (pt) |
| MA (1) | MA32087B1 (pt) |
| MX (1) | MX2010008101A (pt) |
| MY (1) | MY150289A (pt) |
| NZ (1) | NZ586964A (pt) |
| PE (1) | PE20091307A1 (pt) |
| TW (1) | TW200936578A (pt) |
| UY (1) | UY31612A1 (pt) |
| WO (1) | WO2009109710A1 (pt) |
| ZA (1) | ZA201005242B (pt) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2926554B1 (fr) * | 2008-01-22 | 2010-03-12 | Sanofi Aventis | Derives de carboxamides azabicycliques, leur preparation et leur application en therapeutique |
| KR101699822B1 (ko) | 2011-12-21 | 2017-01-25 | 노비라 테라퓨틱스, 인코포레이티드 | B형 간염의 항바이러스성 제제 |
| AR092270A1 (es) | 2012-08-28 | 2015-04-08 | Janssen R&D Ireland | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b |
| PT2961732T (pt) | 2013-02-28 | 2017-06-26 | Janssen Sciences Ireland Uc | Sulfamoil-arilamidas e utilização das mesmas como medicamentos para o tratamento de hepatite b |
| EA027068B1 (ru) | 2013-04-03 | 2017-06-30 | Янссен Сайенсиз Айрлэнд Юси | Производные n-фенилкарбоксамида и их применение в качестве лекарственных препаратов для лечения гепатита b |
| JO3603B1 (ar) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي |
| JP6441315B2 (ja) | 2013-05-17 | 2018-12-19 | ヤンセン・サイエンシズ・アイルランド・ユーシー | スルファモイルチオフェンアミド誘導体およびｂ型肝炎を治療するための医薬品としてのその使用 |
| US10450270B2 (en) | 2013-07-25 | 2019-10-22 | Janssen Sciences Ireland Uc | Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
| MX368158B (es) | 2013-10-23 | 2019-09-20 | Janssen Sciences Ireland Uc | Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b. |
| US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| MX2016009449A (es) | 2014-02-05 | 2016-10-13 | Novira Therapeutics Inc | Terapia de combinacion para el tratamiento de infecciones por virus de la hepatitis b (vhb). |
| EA035848B1 (ru) | 2014-02-06 | 2020-08-20 | Янссен Сайенсиз Айрлэнд Юси | Производные сульфамоилпирроламида и их применение в качестве медикаментов для лечения гепатита b |
| WO2016149581A1 (en) | 2015-03-19 | 2016-09-22 | Novira Therapeutics, Inc. | Azocane and azonane derivatives and methods of treating hepatitis b infections |
| US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
| RS62639B1 (sr) | 2015-07-06 | 2021-12-31 | Alkermes Inc | Hetero-halo inhibitori histonskih deacetilaza |
| EP3319968A1 (en) | 2015-07-06 | 2018-05-16 | Rodin Therapeutics, Inc. | Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase |
| AU2016330964B2 (en) | 2015-09-29 | 2021-04-01 | Novira Therapeutics, Inc. | Crystalline forms of a hepatitis B antiviral agent |
| CN105820104B (zh) * | 2016-03-10 | 2018-12-11 | 温州医科大学 | 一种具有抗炎作用的吲哚-2-酰胺类化合物及其在制备抗炎药物中的应用 |
| SG11201808949SA (en) | 2016-04-15 | 2018-11-29 | Novira Therapeutics Inc | Combinations and methods comprising a capsid assembly inhibitor |
| RS62959B1 (sr) | 2017-01-11 | 2022-03-31 | Alkermes Inc | Biciklični inhibitori histon-deacetilaze |
| MD3664802T2 (ro) | 2017-08-07 | 2022-07-31 | Alkermes Inc | Inhibitori biciclici ai deacetilazei histonei |
| CA3090125A1 (en) | 2018-03-14 | 2019-09-19 | Janssen Sciences Ireland Unlimited Company | Capsid assembly modulator dosing regimen |
| AU2019203034B1 (en) | 2018-07-25 | 2019-09-26 | Hanmi Pharm. Co., Ltd. | Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same |
| KR101954370B1 (ko) | 2018-07-25 | 2019-03-05 | 한미약품 주식회사 | 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물 |
| US11096931B2 (en) | 2019-02-22 | 2021-08-24 | Janssen Sciences Ireland Unlimited Company | Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases |
| EP3966205A1 (en) | 2019-05-06 | 2022-03-16 | Janssen Sciences Ireland Unlimited Company | Amide derivatives useful in the treatment of hbv infection or hbv-induced diseases |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200403223A (en) * | 2002-02-15 | 2004-03-01 | Glaxo Group Ltd | Novel compounds |
| US20050197364A1 (en) * | 2003-10-07 | 2005-09-08 | Kelly Michael G. | Amide compounds as ion channel ligands and uses thereof |
| WO2005072681A2 (en) * | 2004-01-23 | 2005-08-11 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments of inflammatory and neurotic pain. |
| FR2888847B1 (fr) * | 2005-07-22 | 2007-08-31 | Sanofi Aventis Sa | Derives de n-(heteriaryl)-1-heteorarylalkyl-1h-indole-2- carboxamides, leur preparation et application en therapeutique |
| FR2897061B1 (fr) * | 2006-02-03 | 2010-09-03 | Sanofi Aventis | Derives de n-heteroaryl-carboxamides tricycliques contenant un motif benzimidazole, leur preparation et leur application en therapeutique. |
| FR2903985B1 (fr) * | 2006-07-24 | 2008-09-05 | Sanofi Aventis Sa | Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique |
| FR2904316B1 (fr) * | 2006-07-31 | 2008-09-05 | Sanofi Aventis Sa | Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique. |
| FR2910473B1 (fr) * | 2006-12-26 | 2009-02-13 | Sanofi Aventis Sa | Derives de n-(amino-heteroaryl)-1h-pyrrolopyridine-2- carboxamides, leur preparation et leur application en therapeutique. |
-
2008
- 2008-01-23 FR FR0800343A patent/FR2926553B1/fr not_active Expired - Fee Related
-
2009
- 2009-01-20 AU AU2009221032A patent/AU2009221032B2/en not_active Ceased
- 2009-01-20 MY MYPI2010003446A patent/MY150289A/en unknown
- 2009-01-20 CA CA2712921A patent/CA2712921C/fr not_active Expired - Fee Related
- 2009-01-20 KR KR1020107018568A patent/KR20100115358A/ko not_active Application Discontinuation
- 2009-01-20 BR BRPI0906634-9A patent/BRPI0906634A2/pt not_active IP Right Cessation
- 2009-01-20 JP JP2010543541A patent/JP5508287B2/ja not_active Expired - Fee Related
- 2009-01-20 WO PCT/FR2009/000054 patent/WO2009109710A1/fr active Application Filing
- 2009-01-20 CN CN200980109255.9A patent/CN102143956B/zh not_active Expired - Fee Related
- 2009-01-20 EP EP09718226A patent/EP2235003B1/fr active Active
- 2009-01-20 MX MX2010008101A patent/MX2010008101A/es active IP Right Grant
- 2009-01-20 NZ NZ586964A patent/NZ586964A/en not_active IP Right Cessation
- 2009-01-20 EA EA201070874A patent/EA201070874A1/ru unknown
- 2009-01-21 PE PE2009000067A patent/PE20091307A1/es not_active Application Discontinuation
- 2009-01-21 AR ARP090100176A patent/AR070214A1/es not_active Application Discontinuation
- 2009-01-22 CL CL2009000127A patent/CL2009000127A1/es unknown
- 2009-01-22 TW TW098102666A patent/TW200936578A/zh unknown
- 2009-01-23 UY UY031612A patent/UY31612A1/es not_active Application Discontinuation
-
2010
- 2010-07-19 IL IL207079A patent/IL207079A0/en unknown
- 2010-07-21 US US12/840,665 patent/US8399491B2/en not_active Expired - Fee Related
- 2010-07-22 ZA ZA2010/05242A patent/ZA201005242B/en unknown
- 2010-07-22 CO CO10089495A patent/CO6220974A2/es not_active Application Discontinuation
- 2010-08-17 MA MA33095A patent/MA32087B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| FR2926553A1 (fr) | 2009-07-24 |
| CL2009000127A1 (es) | 2010-02-12 |
| CA2712921C (fr) | 2016-08-02 |
| UY31612A1 (es) | 2009-08-31 |
| IL207079A0 (en) | 2010-12-30 |
| AU2009221032A1 (en) | 2009-09-11 |
| US8399491B2 (en) | 2013-03-19 |
| CN102143956A (zh) | 2011-08-03 |
| KR20100115358A (ko) | 2010-10-27 |
| ZA201005242B (en) | 2011-09-28 |
| CA2712921A1 (fr) | 2009-09-11 |
| JP2011510052A (ja) | 2011-03-31 |
| EA201070874A1 (ru) | 2011-02-28 |
| MY150289A (en) | 2013-12-31 |
| EP2235003B1 (fr) | 2012-12-19 |
| TW200936578A (en) | 2009-09-01 |
| AU2009221032B2 (en) | 2013-09-26 |
| PE20091307A1 (es) | 2009-09-21 |
| NZ586964A (en) | 2012-06-29 |
| FR2926553B1 (fr) | 2010-02-19 |
| CN102143956B (zh) | 2014-04-23 |
| WO2009109710A1 (fr) | 2009-09-11 |
| EP2235003A1 (fr) | 2010-10-06 |
| MA32087B1 (fr) | 2011-02-01 |
| MX2010008101A (es) | 2010-08-04 |
| US20110009365A1 (en) | 2011-01-13 |
| AR070214A1 (es) | 2010-03-25 |
| JP5508287B2 (ja) | 2014-05-28 |
| CO6220974A2 (es) | 2010-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0906634A2 (pt) | Drivados de indol 2-carboxamidas e de azaindol 2-carboxamidas substituídos por grupo sinanila, sua preparação e sua aplicação em terapêutica | |
| DK2049525T3 (da) | N-laminoheteroaryl)-1H-indol-2-carboxamid-derivater, og fremstilling og terapeutisk anvendelse deraf | |
| CY2016053I1 (el) | Μεθοδοι αγωγης χρησιμοποιωντας φαρμακευτικες ουσιες συλληψης αμμωνιας | |
| BRPI0918868A2 (pt) | moduladores do receptor de nmda e usos dos mesmos | |
| BRPI0918652A2 (pt) | Composições farmacêuticas e métodos de libração relacionadas. | |
| BRPI0906436A2 (pt) | Derivados de ftalazinona | |
| BRPI0916588A2 (pt) | cobertor, produtos correlacionados e métodos de produção dos mesmos | |
| BRPI0914942A2 (pt) | Compostos de oxindol | |
| BRPI0919331A2 (pt) | derivados de pirazolo piridina, composições farmacêuticas e métodos associados | |
| HK1149762A1 (en) | Substituted indole derivatives | |
| BRPI0809221A2 (pt) | indol carboxamidas como inibidores de ikk2 | |
| BRPI0906357A2 (pt) | Derivados de oxazepinopirimidona arilamida substituídos | |
| BRPI0914651A2 (pt) | conjunto de cunha e soquete | |
| BRPI0907963A2 (pt) | Derivados de indazola | |
| BRPI0921230A2 (pt) | agonistas de receptor de neuropeptídeos-2 (y-2r) e usos dos mesmo. | |
| DK2238110T3 (da) | 5.6-bisaryl-2-pyridin-carboxamid-derivater, fremstilling heraf og terapeutisk anvendelse heraf som urotensin II-receptorantagonister | |
| BRPI0921947A2 (pt) | formulações de proteína terapêutica | |
| BRPI0908893A2 (pt) | Modulação enzimática e de receptores | |
| IL207629A0 (en) | Novel 3-aminoalkyl-1,3-dihydro-2h-indol-2-one derivatives, preparation thereof and therapeutic use thereof | |
| BRPI1014904A2 (pt) | derivados de quinazolinadiona, preparação dos mesmos e vários usos terapêuticos dos mesmos. | |
| BRPI0915627A2 (pt) | compostos derivados de indol, composições farmacêuticas que os contêm, e seus usos | |
| ATE527249T1 (de) | Indole | |
| BRPI0822143A2 (pt) | derivados de dicicloaza-alcano, processos de preparação e usos médicos dos mesmos | |
| BRPI1010514A2 (pt) | derivados de indol e métodos para tratamento antiviral | |
| IL209718A0 (en) | Substituted 7-sulfanylmethyl, 7-sulfinylmethyl and 7-sulfonylmethyl indoles and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 10A ANUIDADE. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2497 DE 13-11-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |